GSK gave AGEN $9 million for the "First Right of Negotiation" earlier this year and to add an additional indication (vaccine). AGEN's adjuvant, QS-21, is in 2/3rds of their future vaccine pipeline including the Malaria vaccine and Mage-A3 vaccines. Any thoughts anyone? It sounds like they need to get AGEN or at least get them to sell GSK QS-21. Thoughts?
It seems TB Phase IIb news was quietly leaked with another indication using AGEN's QS-21 adjuvant. Malaria out before the end of the year...with QS-21 and Non small cell lung cancer - mid year next year. With JNJ/PFE/ELN consortium and ACC-001 with QS-21 - going to Phase III per AGEN's CEO...seems the window for GSK to get AGEN as cheap as possible is closing.